Background
Jade Teakell
Shedding Light on the Dense Matter of C3 ...

This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.

Shedding Light on the Dense Matter of C3 Glomerulopathy
Background
swapnil hiremath
Healing, Hype, or Harm: The NefIgArd trial

This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

Healing, Hype, or Harm: The NefIgArd trial
Background
Cristina Adriana Popa
PRAECISely Predicting Preeclampsia

This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.

PRAECISely Predicting Preeclampsia
Background
swapnil hiremath
The Worldwide Shadow of Kidney Disease

This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.

The Worldwide Shadow of Kidney Disease
Background
swapnil hiremath
The PROTECT-V platform - RENALISM no more?

This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.

The PROTECT-V platform - RENALISM no more?

NEJM

HDF vs HD: Need for CONVINCE-ing Evidence

HDF vs HD: Need for CONVINCE-ing Evidence

This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?

The Fluid Wars Return: Can we restore Balance to the field

The Fluid Wars Return: Can we restore Balance to the field

March 13/14 we will discuss the pair of trials in NEJM from Vanderbilt: comparing balanced solutions to normal saline in critically ill & not ill patients. Join us for the next #NephJC to parse through SMART & SALT-ED

Will PRESERVE preserve the contrast AKI status quo?

Will PRESERVE preserve the contrast AKI status quo?

This week, we will discuss the fresh-off-the-press NEJM paper on the utility of using NAC (vs placebo) or bicarb-based hydration (vs saline) in preventing contrast AKI. A medical reversal that has taken almost 2 decades...

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes. 

#NephJC on desensitization & the winners of the #NEJMCup

This was another great #NephJC. Notable for many firsts:

The transcripts and storifys are also already done - and up on the page, due to uber-fast curation from Hector.

Lastly, we have the pleasure of announcing the winners of the coveted #NEJMCup. There were many great tweets, so it took some time to sift through all the nominees. Here are the winning tweets:

Congratulations, Kevin and Sian! Your #NEJMCups should be on the way soon, courtesy of the New England Journal of Medicine.

Announcing the #NEJMCup for the next #NephJC, courtesy @NEJM

We are discussing an NEJM article next week (on that note check out the summary, written by Matt Graham-Brown). The hurdle? Its behind a subscriber-only wall - and this is an issue that has come up as a barrier for many of us not in academia or with a personal subscription to the Journal. However, the nice people at the Journal have kindly agreed to make it easily accessible for #NephJC readers - use the link on our summary page, and you will get the full text. 

But there is more good news. Like what we have done in the past with JAMA, the best tweet of the night will get a prize. One for each chat. 

The #NEJMCup!

The #NEJMCup!

Lastly, thanks to Lisa Rosenbaum for opening to doors to NEJM for us.